15 results about "Rifaximine" patented technology

Provided herein are solid dispersions comprising rifaximin and pharmaceutical compositions and uses thereof.

Provided herein are pharmaceutical compositions, therapeutic combinations, devices and methods for treating, ameliorating, reversing, causing the remission of, and / or preventing (acting as a prophylaxis, or preventing the initiation of) an inflammatory bowel disorder (IBD) or inflammatory bowel disease (IBD), Ulcerative Colitis; Crohn's disease; J-pouch; fistulising Crohn's disease; a Colitis which can be microscopic, lymphocytic or collagenous; an eosinophilic colitis; indeterminate colitis; idiopathic colitis; diverticulosis and diverticulitis; relapsing diverticulitis; constipation associated inflammatory bowel disease and / or small intestinal bacterial overgrowth; Irritable Bowel Syndrome (IBS) with or without diarrhoea, constipation or pain predominant IBS; periodontitis; rheumatoid arthritis; respiratory infections, appendicitis, vascular disorders such as thrombophlebitis; bacteremia; osteomyelitis; septic shock; Alzheimer's disease; Lemierre syndrome (postanginal sepsis); colonic polyps or adenomas (optionally hyperplastic, adenomatous or serrated adenomas) or preventing the growth of colonic polyps or adenomas, bowl cancer, or metastases (optionally preventing the initiation or promotion of bowl cancer or metastasis); pharyngitis; otitis; sinusitis; and any disease, symptom or condition caused or exacerbated by a Fusobacteria (optionally, a F. nucleatum or F. varium) infection. In alternative embodiments, pharmaceutical compositions comprise rifaximin alone or in combination with other antibiotics or drugs.

This invention discloses a rifaximin nanoemulsion, its preparation method, and its application, belonging to the field of veterinary drug technology. The technical solution includes a rifaximin nanoemulsion comprising rifaximin, a compound essential oil, a surfactant, a co-surfactant, and water; the compound essential oil includes oregano oil, cinnamon oil, and tea tree oil. This invention prepares a rifaximin nanoemulsion using a compound of oregano, cinnamon, and tea tree oils as the oil phase, exhibiting both high antibacterial efficiency and high safety. The three essential oils have a synergistic antibacterial effect, complementing rifaximin through multi-target action, broadening the antibacterial spectrum, and showing significant inhibitory effects against various bacteria and fungi. It can enhance uterine smooth muscle contraction function by stimulating the synthesis and secretion of prostaglandins and oxytocin, providing potential support for uterine involution and endometrial repair. After administration, it can effectively reduce the number of inflammatory cells such as leukocytes and neutrophils in experimental dairy cows, significantly reduce purulent vaginal discharge, and restore the softness and elasticity of the uterus upon rectal examination.

The present invention relates to rifaximin for use in methods of treating or preventing sarcopenia in a human patient with liver disease, such as a patient with cirrhosis.

This invention discloses a method for preparing rifamycin O, an intermediate of rifaximin, in the field of organic synthesis. The method uses rifamycin B as a starting material, and rifamycin O is obtained by oxidative coupling under the action of a solvent and a catalyst; the catalyst is a FeCl3 / Al2O3 solid oxidant. This invention uses FeCl3 / Al2O3 solid oxidant to oxidize rifamycin B to prepare rifamycin O. The oxidative coupling reaction conditions are mild, the post-processing is simple, the process cycle is short, and the yield and product purity are high, making it suitable for industrial production.

Provided herein are GI specific rifaximin release compositions which can be formulated for targeted delivery of rifaximin to one or more portions of the GI tract. Methods of treating diseases and disorders with the disclosed compositions are also provided.

Methods of treatment of sickle cell disease are based on the administration of the antibiotic compound rifaximin.

Provided herein are GI specific rifaximin release compositions which can be formulated for targeted delivery of rifaximin to one or more portions of the GI tract. Methods of treating diseases and disorders with the disclosed compositions are also provided.

Provided herein are solid dispersions comprising rifaximin and pharmaceutical compositions and uses thereof.

The present invention relates to rifaximin for use in methods of treating or preventing sarcopenia in a human patient with liver disease, such as a patient with cirrhosis.

The present invention relates to a novel combination of rifaximin and probiotic yeast, the pharmaceutical compositions containing the combination as well as their use in therapy, in particular in the prevention and / or treatment of intestinal diseases.

The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.

The present invention relates to a novel synergistic combination of rifaximin and clarithromycin. The invention also relates to a kit comprising such combination, and such combination for use as pharmaceuticals, for instance in the treatment of bacterial diseases, including diseases caused by pathogenic mycobacteria such as clarithromycin-resistant and clarithromycin non-resistant non-tuberculosis mycobacteria.

Safe and effective methods for treating a subject suffering from cortisol excess of and in need of concomitant administration of mifepristone along with a CYP3A4 inducer are disclosed herein. The CYP3A4 inducer may be, for example, mitotane, rifampin (also known as rifampicin), rifabutin, rifapentin, phenobarbital, phenytoin, carbamazepine, or St. John's wort. In embodiments, the CYP3A4 inducer is a strong CYP3A4 inducer. In embodiments, the CYP3A4 inducer is a moderate CYP3A4 inducer. In embodiments, the CYP3A4 inducer may be any CYP3A4 inducer. Mifepristone may be orally administered. Mifepristone may be administered with food.

The invention discloses a method for preparing rifaximin intermediate rifamycin O. The method comprises the following steps: taking rifamycin B as an initial raw material, taking a continuous flow separation type electrolytic cell as an electroreactor, adopting an ion exchange membrane to isolate a cathode electrolyte and an anode electrolyte, taking the cathode electrolyte as an alkaline solution, and carrying out electrochemical oxidation to prepare the rifaximin intermediate rifamycin O. The method comprises the following steps: preparing a cathode liquid storage chamber and an anode liquid storage chamber, pumping the cathode liquid storage chamber and the anode liquid storage chamber into the anode liquid storage chamber by adopting a circulating pump, ensuring the continuous flow of the solution in the electrolysis process, carrying out electrochemical oxidation reaction at the temperature of 0-100 DEG C and the current of 1-100mA / cm < 2 >, carrying out rotary evaporation and recrystallization after the reaction is finished to obtain a solid, and carrying out vacuum drying to obtain the rifamycin B solid. And carrying out suction filtration to obtain a solid, and drying to obtain rifamycin O. The electrochemical oxidation method is mild in condition, green, free of pollution and high in yield, use of extra oxidizing agents and catalysts is avoided, the solvent can be recycled, and the method is suitable for industrial amplification generation.